# A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

> **NCT05864846** · PHASE4 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

## Interventions

- **DRUG:** Cannabidiol Oral Solution [Epidiolex]

## Key facts

- **NCT ID:** NCT05864846
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-29
- **Primary completion:** 2026-04-06
- **Final completion:** 2026-04-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864846, "A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05864846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*